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Abstract: Bisphosphonates and denosumab are commonly used antiresorptive therapies in patients with
bone metastasis and osteoporosis. Medication-related osteonecrosis of the jaw (MRONJ) is a serious side
effect of these drugs, and infection has been recognized as a contributing factor. Current therapeutic
options for MRONJ show limited effectiveness, therefore necessitating novel treatment strategies. Bis-
phosphonates have recently been reported to induce the expression of antimicrobial peptides (AMPs), an
inherent component of the immune system. Therefore, the aim of the present study was to investigate
and compare the influence of the anti-RANKL antibody denosumab and bisphosphonates on the gene
expression of selected AMPs: human ฀-defensin-1, human ฀-defensin-3, human ฀-defensin-1, and human
฀-defensin-3. Bone specimens were collected from patients with MRONJ who had been treated with
bisphosphonates (n = 6) or denosumab (n = 6), and from healthy subjects (n = 6) with no history of
treatment with bone metabolism-influencing drugs. Reverse transcription-quantitative polymerase chain
reaction was used to quantify the expression levels of selected AMPs. Samples from patients treated with
denosumab showed significantly higher mRNA expression of human ฀-defensin-3 and human ฀-defensin-3
than those from healthy subjects. This finding is similar to previously described upregulated expression
of human defensins in patients with MRONJ after bisphosphonates treatment. This suggests that the
elevated expression of defensins may be at least a part of the mechanism underlying the pathogenesis of
osteonecrosis induced by antiresorptive therapies, which can serve as a new target for potential treatment
of MRONJ.
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A B S T R A C T   
Bisphosphonates and denosumab are commonly used antiresorptive therapies in patients with bone metastasis 
and osteoporosis. Medication-related osteonecrosis of the jaw (MRONJ) is a serious side effect of these drugs, and 
infection has been recognized as a contributing factor. Current therapeutic options for MRONJ show limited 
effectiveness, therefore necessitating novel treatment strategies. Bisphosphonates have recently been reported to 
induce the expression of antimicrobial peptides (AMPs), an inherent component of the immune system. There-
fore, the aim of the present study was to investigate and compare the influence of the anti-RANKL antibody 
denosumab and bisphosphonates on the gene expression of selected AMPs: human α-defensin-1, human 
α-defensin-3, human β-defensin-1, and human β-defensin-3. Bone specimens were collected from patients with 
MRONJ who had been treated with bisphosphonates (n = 6) or denosumab (n = 6), and from healthy subjects 
(n = 6) with no history of treatment with bone metabolism-influencing drugs. Reverse transcription-quantitative 
polymerase chain reaction was used to quantify the expression levels of selected AMPs. Samples from patients 
treated with denosumab showed significantly higher mRNA expression of human α-defensin-3 and human 
β-defensin-3 than those from healthy subjects. This finding is similar to previously described upregulated 
expression of human defensins in patients with MRONJ after bisphosphonates treatment. This suggests that the 
elevated expression of defensins may be at least a part of the mechanism underlying the pathogenesis of 
osteonecrosis induced by antiresorptive therapies, which can serve as a new target for potential treatment of 
MRONJ.   
1. Introduction 
Antiresorptive drugs that influence bone metabolism, such as 
bisphosphonates and the receptor activator of nuclear factor κB ligand 
(RANKL) antibody denosumab, are important as treatment options for 
osteoporosis and as a supportive therapy for osseous metastatic malig-
nancies, by regulating the resorption of bone [1]. However, since their 
introduction, the incidence of bisphosphonate-related osteonecrosis of 
the jaw (BRONJ) has increased steadily [2]. In 2010, Taylor et al. [3] 
reported the first case of osteonecrosis induced by anti-RANKL antibody 
(denosumab), with similar radiological, clinical, and histological 
characteristics as observed in BRONJ lesions. A comparative study in 
2013 showed that the risk of development of osteonecrosis of the jaw 
was similar between patients treated with the bisphosphonate zoledro-
nate and denosumab [4]. 
Considering these general findings, in 2014, the American Associa-
tion of Oral and Maxillofacial Surgeons introduced the term “medica-
tion-related osteonecrosis of the jaw” (MRONJ), which clinically 
manifests as “exposed necrotic bone (or bone that can be probed through 
an intraoral or extraoral fistula) in the mandible or maxilla for at least 8 
weeks’ duration, with or without the presence of pain or infection, in a 
patient with no history of radiation therapy or obvious metastatic 
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diseases in the jaws and under current or previous treatment with 
antiresorptive or antiangiogenic agents” [5]. Antiangiogenic drugs are 
used for tumor patients to interfere with various steps in angiogenesis, 
thus inhibiting tumor growth [6]. Currently, there are no globally 
accepted treatment options for MRONJ. Treatment strategies range from 
conservative non-surgical therapy to early surgical intervention. The 
extent of an intervention depends on disease stage, presented symptoms, 
and other factors such as the underlying morbidity and comorbidities 
[5]. Therefore, further research is needed to understand the underlying 
pathogenic mechanism contributing to MRONJ for the development of 
effective targeted therapies. 
As key elements of innate immunity, human antimicrobial peptides 
(AMPs), such as defensins, play a critical role against microbial patho-
gens [7]. Furthermore, AMPs are involved in other biological functions 
such as apoptosis, wound healing, and immune modulation [7]. Addi-
tionally, AMPs are responsible for mediating surface immunity. To avoid 
bacterial invasion, the expression of AMPs on mucosal and dermal sur-
faces is increased to stabilize the epithelial barrier [8]. Therefore, pro-
tecting the bone from pathogenic flora is an important function of AMPs. 
Human defensins are small cationic peptides with a large number of 
hydrophobic amino acids. Their interaction with the anionic membranes 
of gram-negative and gram-positive bacteria and encapsulated viral and 
fungal pathogens, facilitates the destruction of the cellular membranes 
and interferes with the intracellular functions of these microorganisms 
[9]. Among the numerous defensins discovered to date, human 
β-defensins (hBDs), especially hBD-1 and -3, are known to have a 
broad-spectrum antimicrobial activity and constitutional similarities 
[10]. Human α-defensins (hADs) have comparable functions that vary 
depending on the type of bacteria [7]. In addition, they show chemo-
tactic activity and modulate inflammation by influencing the expression 
of cytokines and adhesion molecules [11]. In 2005, Warnke et al. 
detected the expression of hBD-1 and -3 in chronically diseased and 
healthy jawbones, thereby providing the first confirmation of the 
inherent immunological function of bone [12]. 
Elevated hBD levels have been detected in osteomyelitis of the jaw, 
and Stockmann et al. quantified their expression in MRONJ compared 
with expression in osteoradionecrosis and healthy jawbones (control) 
[13]. Their results confirmed that the jawbone of MRONJ patients 
expressed higher levels of beta-defensins when compared to healthy 
uninfected jawbones. Elevated human defensin levels indicate that 
defective defensin expression in bone might lead to inflammation and 
subsequently osteonecrosis of the jawbone [13]. 
Based on this background, the aim of the present study was to 
investigate and compare the effects of antiresorptive drugs on the gene 
expression of selected α- and β-defensins in jawbone samples from pa-
tients with MRONJ compared to that in healthy jawbones. We report 
increased mRNA expression of defensins mediated by denosumab 
treatment similar to that induced by bisphosphonate therapy in patients 
with MRONJ. 
2. Materials and methods 
2.1. Patients and control subjects 
This prospective study, with the subsequent use of biological mate-
rial, was conducted in accordance with the Declaration of Helsinki on 
Ethical Principles for Medical Research. The cantonal ethics committee 
of Zurich (Approval No. F-42880-06-0) approved the study, and prior 
written informed consent was obtained from all individual participants 
for the study. 
Bone samples of 12 patients diagnosed with MRONJ, six patients 
treated with bisphosphonates and six patients treated with denosumab, 
for more than 12 months, were used in the study. Patients who previ-
ously used antiresorptive drugs (both denosumab and bisphosphonates) 
and those with asymptomatic MRONJ not requiring a surgical inter-
vention were excluded. 
The samples were harvested during therapeutic necrosectomy of the 
maxilla and/or mandible (which are otherwise routinely discarded) and 
included the transitional zone between non-necrotic and necrotic bones. 
Bone samples for the control group were harvested from six healthy 
individuals, with no history of bone metabolism-influencing drugs or 
serious diseases of the bone (e.g. osteoporosis). The samples were ob-
tained during the osteotomy and/or extraction of their wisdom teeth. 
2.2. RNA purification and reverse transcription 
The total RNA was extracted and purified from the bone samples 
using a commercial RNA extraction kit (miRNeasy Mini Kit; QIAGEN, 
Hilden, Germany) according to the manufacturer’s protocol. The con-
centration and purity of the total RNA were determined by spectro-
photometric measurements at 260 and 280 nm (NanoDrop 2000®; 
Thermo Fisher Scientific, Waltham, MA, USA). The extracted RNA 
samples were frozen and stored at - 80 ◦C until analysis. 
The total RNA (400 ng) was reverse transcribed into cDNA using the 
iScript™ cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). The cDNA 
samples were diluted to 1/15 and stored at −20 ◦C (total volume 
600 μL). SsoAdvanced™ PreAmp Supermix® (Bio-Rad) was used ac-
cording to the manufacturer’s protocol to provide unbiased pre-
amplification, enabling to obtain more data from a limited sample size. 
The cDNA was used as a template to determine the basal mRNA 
expression level of human hAD-1, hAD-3, hBD-1, and hBD-3 in each of 
the 18 samples by qPCR. Patient samples were divided into three groups: 
Group 1 comprised the six samples from patients treated with denosu-
mab, Group 2 comprised the six samples from patients treated with 
bisphosphonates, and Group 3 comprised the six samples from healthy 
subjects. The results of the two pathological sample groups (Groups 1 
and 2) were independently compared with those of the healthy sample 
group (Group 3). 
2.3. Quantitative polymerase chain reaction (qPCR) 
PCRs were performed using 10 μL of diluted reverse transcriptase 
(RT) product per reaction according to the manufacturer’s protocol 
(SsoAdvanced™ Universal SYBR® Green Supermix; Bio-Rad). The 
primers used in this study were purchased from Bio-Rad and are listed in 
Table 1. In addition to the selected defensins, the housekeeping gene 
RPS18 was simultaneously amplified with each gene of interest as an 
internal reference. Amplification was conducted on the CFX Connect 
Real-Time PCR System (Bio-Rad). 
2.4. Statistics 
Relative gene expression levels were determined using the 2ΔΔCT 
method [14], and these data are reported in the form of boxplots using 
the ΔCT values (ΔCT = CT target gene - CT reference gene). t-test of the 
ΔCT values was used to determine differences in the expression profiles 
using XLSTAT-Excel Statistical Calculator (Microsoft, Redmond, WA, 
Table 1 





Primer ID (catalogue 
number) 
hAD-1 Human α-defensin- 
1 
Bio-Rad qHsaCID0037384 
hAD-3 Human α-defensin- 
3 
Bio-Rad qHsaCED0056797 
hBD-1 Human β-defensin- 
1 
Bio-Rad qHsaCID0015106 
hBD-3 Human β-defensin- 
3 
Bio-Rad qHsaCED0037167 
RPS18 Ribosomal protein 
S 18 
Bio-Rad qHsaCED0037454  
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USA). 
Results with a p-value of <0.05 were considered statistically 
significant. 
3. Results 
The average age at surgery was 71.9 ± 10.1 years in the MRONJ 
group (Table 2) and 24.8 ± 4.2 years in the control group (Table 3). 
3.1. hAD-1 
There was no significant difference in hAD-1 mRNA expression be-
tween the healthy and pathological groups (Fig. 1). hAD-1 mRNA 
expression in the healthy group was higher than that in the denosumab 
group but lower than that in the bisphosphonate group. These differ-
ences were not statistically significant. By dividing the pathological 
groups according to the treatment, bisphosphonates or denosumab, we 
noticed that there was a significant difference with respect to an increase 
in the mRNA expression of hAD-1 in the bisphosphonate group 
compared with the denosumab group. 
3.2. hAD-3 
There was a significant increase in hAD-3 mRNA expression in both 
pathological groups, denosumab and bisphosphonates, compared to the 
healthy controls (Fig. 1). 
3.3. hBD-1 
All samples showed low mRNA expression of hBD-1 (Fig. 2). There 
was no significant difference in hBD-1 mRNA expression among the 
three groups, with the lowest expression observed in the healthy group. 
3.4. hBD-3 
The mRNA expression of hBD-3 in the healthy group was almost zero 
(Fig. 2) compared with that in the denosumab group, which was 
significantly increased. Compared with the healthy group, the mRNA 
expression of hBD-3 in the bisphosphonate group was also increased, but 
with no significant difference. 
4. Discussion 
MRONJ is a devastating complication of antiresorptive therapies 
defined by the exposure of bone and accompanied by pain, swelling, and 
infection of soft tissues. Currently, there are no globally accepted 
treatment protocols for MRONJ, resulting in a high rate of recurrence 
and persistence of symptoms. In the present study, we determined and 
compared the effects of antiresorptive drugs (bisphosphonates and 
denosumab) on the gene expression of selected human α- and 
β-defensins in the jawbone samples harvested from patients with 
MRONJ and healthy individuals. 
AMPs are key elements in the innate immune system and provide the 
first line of defense in the skin against invading microbes [10]. In this 
context, Nomura et al. investigated the expression of innate immune 
response genes, including that of hBDs, in two of the most common 
chronic skin diseases: atopic dermatitis and psoriasis. Although AMPs 
were detected in small amounts in normal skin keratinocytes of healthy 
individuals, large amounts were found to be produced in response to 
stimulation with injury or inflammation, and the atopic dermatitis le-
sions had lower levels of hBD than psoriasis lesions [15]. In particular, 
the authors showed that the most effective transcriptional stimulation of 
hBD-3 was achieved by a combination of tumor necrosis factor-α and 
interferon-γ, two cell-signaling proteins (cytokines) involved in systemic 
inflammation and the acute phase reaction [15]. These findings could 
explain the high hBD-3 mRNA expression observed in the MRONJ 
samples in this study, given that our patients were in an advanced dis-
ease stage, accompanied by infection and requiring surgical interven-
tion. Despite many theories explaining the etiopathogenesis of MRONJ, 
several studies have highlighted infection as a major and not just sec-
ondary event, which stimulates a chronic inflammatory immune 
response [16]. This response would cause the upregulation of cytokines 
to ultimately upregulate hBD-3 expression with the progression of the 
infection [16]. 
Consistently, Warnke et al. confirmed that the expression of AMPs 
“appears to be upregulated in chronically infected osteoradionecrotic 
mandibular bone” [12]. 
hBD-1 and -3 were first identified in the mineralized bone matrix and 
cytoplasm of osteocytes of chronically infected mandibular bone sam-
ples [12]. Although expressed in lower quantities, the expression levels 
of both molecules were equal in each of uninfected bone types, including 
those in the controls [12]. These findings may reflect upregulation of 
AMP expression due to chronic infection and are comparable with our 
results for hBD-1 and -3. 
Surgical intervention and extended antibiotic therapy are currently 
the leading therapeutic options for MRONJ. Zirk et al. reported that 
different antibiotic regimens and local submucosal infection affect the 
clinical course of patients suffering from MRONJ, particularly in 
advanced disease stages [17]. However, antimicrobial resistance among 
Table 2 
Demographic data of the patients.  
Sample Sex Age (years) Antiresorptive drug Disposal Location Underlying Diagnosis 
1 m 75 Denosumab s.c. Upper jaw Cancer 
2 f 75 Denosumab s.c. Lower jaw Osteoporosis 
3 m 64 Denosumab s.c. Lower jaw Cancer 
4 f 72 Denosumab s.c. Lower jaw Osteoporosis and Cancer 
5 m 72 Denosumab s.c. Upper jaw Osteoporosis 
6 f 70 Denosumab s.c. Lower jaw Cancer  
1 m 65 Bisphosphonate i.v. Lower jaw Cancer 
2 f 92 Bisphosphonate i.v. Lower jaw Osteoporosis 
3 f 65 Bisphosphonate i.v. Lower jaw Osteoporosis 
4 f 75 Bisphosphonate i.v. Lower jaw Cancer 
5 f 85 Bisphosphonate i.v. Upper jaw Osteoporosis 
6 m 53 Bisphosphonate i.v. Lower jaw Cancer  
Table 3 
Demographic data of the healthy individuals.  
Sample Sex Age (years) Location 
1 f 31 Lower jaw 
2 m 24 Upper jaw 
3 f 23 Lower jaw 
4 m 19 Lower jaw 
5 f 28 Lower jaw 
6 m 24 Upper jaw  
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common bacterial pathogens is noticeably increasing, which is a sub-
stantial challenge in improving treatment outcomes [18]. In fact, the 
World Health Organization named antibiotic resistance as one of the 
“three most important public health threats of the 21st century” [19]. 
Given the decreasing potential of antibiotics as a therapy for MRONJ, 
defensins could be a potential and promising alternative for 
anti-infective compound development. The interaction of defensins with 
molecules of the microbial cell envelope that are directly accessible, 
such as lipopolysaccharides, can be highly specific [20]. Furthermore, 
defensins modulate the immune response regardless of the state of 
resistance of the individual pathogen [20]. Their broad spectra along 
with multifunctional characteristics make AMPs a promising constituent 
for developing therapeutic strategies not only against MRONJ but also 
against multiple other human diseases. 
However, our study had some limitations. The study had a small 
number of patients, and there was no distinction between patients with 
osteoporosis and cancer. Furthermore, there was a large age difference 
between the control and patient groups. 
Future research should focus on whether the administration of 
bisphosphonates and antiresorptive drugs impairs the antimicrobial 
activity of defensins. Furthermore, studies could focus on increased 
hAD-3 mRNA expression in patients treated with antiresorptive drugs 
and elucidate why bisphosphonates and denosumab impair the expres-
sion of hAD-1 in a significantly different way. In addition, these new 
findings related to the pathology and pathomechanism of MRONJ may 
serve as a model for the development of new therapies and prevention 
approaches. 
5. Conclusions 
In the present study, we demonstrated significantly increased mRNA 
expression of selected human defensins (hAD-3 and hBD-3) in MRONJ- 
affected bones in patients treated with anti-RANKL antibody (denosu-
mab). This upregulation was similar to that observed after treatment 
with bisphosphonates; although not to the same extent. These findings 
suggest that human defensins, especially hAD-3 and hBD-3, could be a 
promising and innovative target for the prophylaxis and treatment of 
MRONJ. 
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